988.00
-12.00
(-1.20%)
Real-time:
8:15am BST
LON real-time data - Disclaimer
Currency in GBX unless noted
| Range | 986.50 - 989.00 |
| 52 week | 630.00 - 1,048.00 |
| Open | 989.00 |
| Vol / Avg. | 2,973.00/218,202.00 |
| Mkt cap | 1,951.15M* |
| P/E | 30.25 |
| Div/yield | 6.56/1.06* |
| EPS | 0.33* |
| Shares | 197.48M |
| Beta | - |
| Inst. own | - |
| *GBP |
Events
Aug 21, 2013
Interim 2013 Hikma Pharmaceuticals PLC Earnings Release
Jun 18, 2013
HIKMA PHARMACEUTICALS PLC at Citi European Healthcare Conference
May 16, 2013
Hikma Pharmaceuticals PLC Annual General Meeting
|
|
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | 11.16% | 9.67% |
| Operating margin | 15.91% | 15.04% |
| EBITD margin | - | 21.64% |
| Return on average assets | 7.56% | 6.49% |
| Return on average equity | 14.87% | 12.47% |
| Employees | 6,649 | - |
| Carbon Disclosure Rating | - | - |
Address
13 Hanover Square
LONDON, ENG W1S 1HW
United Kingdom - Map
+44-20-73992760 (Phone)
+44-20-73992761 (Fax)
LONDON, ENG W1S 1HW
United Kingdom - Map
+44-20-73992760 (Phone)
+44-20-73992761 (Fax)
Website links
External links
Analyst Estimates - BusinessWeek
Options - MarketWatch
Research Reports - Reuters
Director Dealings - Yahoo Finance
Discussion Group - Google Finance
Advertisement
Description
Hikma Pharmaceuticals PLC is engaged in the development, manufacture and marketing of a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms. The Company operates in three business segments: Branded, Injectables, and Generics. The majority of its operations are in the Middle East and North Africa region, the United States and Europe. The Company�s operations span over 45 countries and focuses on a range of therapeutic areas. The Company�s other businesses primarily consists of Arab Medical Containers Ltd, a manufacturer of pharmaceutical packaging; and International Pharmaceutical Research Center Ltd, which conducts bio-equivalency studies, and the chemicals division of Hikma Pharmaceuticals Ltd
Officers and directors
| Said Darwazah | Chief Executive Officer, Executive Director | |
| Mazen Samih Talib Darwazah | Executive Vice Chairman of the Board, CEO , Middle East and North Africa | |
| Khalid Nabilsi | Chief Financial Officer | |
| Bassam Wael Rushdi Kanaan | President and Chief Operating Officer, MENA and EU Regions | |
| Michael Raya | President and CEO of West-Ward Pharmaceutical Corp. | |
| Ibrahim Jalal | Senior Corporate Vice President - Technical Affairs | |
| Majda Labadi | Corporate Vice President - Human Resources | |
| Susan Ringdal | Vice President - Investor Relations and Group Goal Compliance,Investor Relations Director | |
| Riad Mishlawi | EU Vice President and Global Head - Injectables | |
| Fadi Nassar | Corporate Vice President - Active Pharmaceutical Ingredients |